Is homozygosity for factor V Leiden a risk factor for myocardial infarction in young women who smoke?

Raj K. Patel; Wendy Ingram; Philip MacCarthy; Roopen Arya

doi:10.1055/s-0037-1616562

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 93(03): 616-617
DOI: 10.1055/s-0037-1616562

Letters to the Editor

Schattauer GmbH

Is homozygosity for factor V Leiden a risk factor for myocardial infarction in young women who smoke?

Raj K. Patel

¹Department of Haematological Medicine, King’s College Hospital, London, U.K.

,

Wendy Ingram

¹Department of Haematological Medicine, King’s College Hospital, London, U.K.

,

Philip MacCarthy

²Department of Cardiology, King’s College Hospital, London, U.K.

,

Roopen Arya

¹Department of Haematological Medicine, King’s College Hospital, London, U.K.

› Author Affiliations

Abstract

Full Text

References

References
1 Rallidis LS, Belesi I C, Manioudaki HS. et al. Myocardial infarction under the age of 36: prevalence of thrombophilia disorders. Thromb Haemost 2003; 90: 272-8.
2 Rosendaal FR, Siscovick SM, Schwartz RK. et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
3 Rosendaal FR, Siscovick SM, Schwartz SM. et al. A common prothrombotic variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-50.
4 Siscovick DS, Schwartz SM, Rosendaal FR. et al. Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb Haemost 1997; 78: 7-12.
5 Tanis BC, Bloemenkamp DG, van den Bosch MA. et al. Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction. Br J Haematol 2003; 122: 471-8.
6 Rees DC, Cox M, Clegg JB. World distribution of FV Leiden. Lancet 1995; 346: 1133-34.
7 Koster T, Rosendaal FR, de Ronde H. et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
8 van der Meer FJM, Koster T, Vandenbroucke JP. et al. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78: 631-5.
9 Holm J, Hillarp Zoller B. et al. Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome. Thromb Haemost 1999; 81: 857-60.
10 Holm J, Zoller B, Svensson PJ. et al. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344: 952-3.
11 Menge H, Faig HG, Lang A. et al. Homozygous form of factor V Leiden mutation as the cause of a myocardial infarction in patient with an unremarkable coronary vascular system?. Deutsche Medizinische Wochenschrift 2001; 126: 684-6.
12 Montaruli B, Voorberg J, Tamponi G. et al. Arterial and venous thrombosis in two Italian families with the factor V Arg506-Gln mutation. Eur J Haematol 1996; 57: 96-100.
13 Van Es RF, Jonker JJ, Verheugt FW. et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT- 2 study): a randomised controlled trial. Lancet 2002; 360: 109-13.
14 Hurlen M, Smith P, Amesen H. et al. Effect of warfarin, aspirin and the two combined, on mortality and thrombo-embolic morbidity after myocardial infarction: the WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J 2000; 34: 168-71.